These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Debes A; Bauer M; Kremer S Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556 [TBL] [Abstract][Full Text] [Related]
28. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology]. Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880 [No Abstract] [Full Text] [Related]
29. Intravenous immunoglobulin: production, uses and side effects. Cowden J; Parker SK Pediatr Infect Dis J; 2006 Jul; 25(7):641-2. PubMed ID: 16804436 [No Abstract] [Full Text] [Related]
33. [Intravenous immunoglobulin infusion treatment for pneumoconiosis complicated with severe asthma in coal miners ]. Zhao JN; Wang P Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2003 Jun; 21(3):234-5. PubMed ID: 14761506 [No Abstract] [Full Text] [Related]
34. Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis. Ellis RJ; Swendson MR; Bajorek J Muscle Nerve; 1994 Jun; 17(6):683-4. PubMed ID: 8196714 [No Abstract] [Full Text] [Related]
35. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P; Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852 [TBL] [Abstract][Full Text] [Related]
37. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071 [TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Lopate G; Pestronk A; Al-Lozi M Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853 [TBL] [Abstract][Full Text] [Related]
39. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. Sorensen R J Manag Care Pharm; 2007 Apr; 13(3):278-83. PubMed ID: 17407395 [No Abstract] [Full Text] [Related]
40. Current perspectives on the use of intravenous immunoglobulin. Dickler HB; Gelfand EW Adv Intern Med; 1996; 41():641-80. PubMed ID: 8903601 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]